Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 379-381, 2004.
Artículo
en Chino
| WPRIM
| ID: wpr-271008
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and adverse reactions of Xeloda in the treatment of recurrent and metastatic breast cancer.</p><p><b>METHODS</b>This clinical study was designed to treat 69 patients with recurrent and metastatic breast cancer with Xeloda, 2500 mg/m(2)/d, twice daily for 2 weeks followed by a 1-week rest period, repeated every 3 weeks.</p><p><b>RESULTS</b>Sixty-nine patients received Xeloda for more than 1 cycle. The overall response rate (CR + PR) was 16.0%, clinical benefit rate (CR + PR + SD > or = 24 months) was 27.5%, disease control rate (CR + PR + SD) was 75.4%. The median time to failure (TTF) was 3 months (range 0.7 - 11 months). The median time to progression (TTP) was 2 months (range 0.7 - 11 months). The median duration of response (CR + PR) was 6 months (range 4 - 11 months). The most common treatment-related adverse events were hand-foot syndrome (HFS) that occurred in 60.8% (42/69) patients mostly as grade I-II. Fifty-five percent (22/40) of patients who had received high dose preventive Vit B6 developed HFS without grade III; while 69% (20/29) of patients who had not received such treatment did develop HFS including 2 patients with grade III. However, there was not significant difference between the two groups.</p><p><b>CONCLUSION</b>Xeloda is an effective and well tolerated treatment in patients with recurrent and metastatic breast cancer. The symptoms of HFS may be relieved by high dose Vit B6 as prevention.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Patología
/
Neoplasias Óseas
/
Neoplasias de la Mama
/
Esquema de Medicación
/
Usos Terapéuticos
/
Desoxicitidina
/
Quimioterapia
/
Capecitabina
/
Fluorouracilo
/
Neoplasias Hepáticas
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Oncology
Año:
2004
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS